-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Eloxx Pharma, Lowers Price Target to $40

Benzinga·10/28/2026 13:47:02
Listen to the news
Guggenheim analyst Vamil Divan maintains Eloxx Pharma (NASDAQ:ELOX) with a Buy and lowers the price target from $43 to $40.